Menu
| Article Index |
|---|
| For Professionals |
| Characteristics of Lynch Syndrome |
| Diagnosis and Management |
| Diagnostic Guidelines |
| Diagnostic Tools for Professionals |
| Recommended Screening Guidelines |
| Genetic Counselors and Laboratories |
| Specific Mutated Genes |
| Other Genetic Cancers |
| All Pages |
RECOMMENDED SCREENING
Colonoscopy: Annually, beginning at age 20-25, or ten years younger than the earliest age of diagnosis in the family, whichever comes first.
Endometrial Sampling: Annually, beginning between ages 30-35
CA-125: For Ovarian Cancer
Transvaginal Ultrasound: For Endometrial and Ovarian Cancer: Annually beginning ages 30-35
Ultrasonography With Cytology: Annually, beginning at age 25-35
Gastroscopy: Annually for individuals with family history of Lynch gastric cancers.
Examination and Review: Family History Review, Discussion of LS - Annually
Dermatological Examination: Including Muir-Torre lesions characterized including, but not all inclusive of sebaceous adenomas, sebaceous epithelioma, basal cell epithelioma with sebaceous differentiation, sebaceous carcinoma and squamous cell cancer (keratoacanthoma type.)
Colon Resection: For individuals with active colon cancer that cannot be removed by colonoscopy. Subtotal colectomy favored with preferences of patient actively elicited. Consider more extensive colectomy for patients with a strong family history of colon cancer or young age. (<50) NCCN 2.2012
Full Abdominal Hysterectomy and Bilateral Salpingo Oopherectomy: Discuss as an option after childbearing years to deter the high risk of gynecological cancers.
Any Other Screening As Deemed Appropriate By the Physician:
Breast cancer has been identified as an integral component of LS based upon mismatch repair germline mutation factors in breast cancer tissues from family members who are not only at high risk, but, moreover, who had Lynch syndrome cancers, such as involving the colorectum. Breast cancer is exceedingly common in the population and, therein, its occurence in Lynch syndrome families could be due to chance, but importantly, a subset will likely be integrally related to a germline mismatch repair Lynch syndrome mutation is some LS families. Therefore, it would be prudent to mount a screening and management program for Lynch syndrome in those families where breast cancer is believed to be an integral lesion.
European studies have evidenced prostate cancer as an integral component of LS based upon mismatch repair germline mutation factors. Annual PSA screenings and prostate examinations are a prudent approach for screening of individuals with the Lynch syndrome.
Modified 11/22/2011